Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 590 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PUSH Clear all
Not listed Not applicable Interventional

mHealth Facilitated Intervention to Improve Medication Adherence Among Persons Living With HIV

NCT05046392
View directory record Official record
Conditions
HIV, Medication Adherence, Telemedicine
Interventions
Face-to-Face ART Adherence Intervention, Carium Mobile Health Platform
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects

NCT02169934
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled TRV130
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

NCT00005908
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 17, 2026, 10:44 AM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

NCT03826602
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Tucatinib, Metformin, Iohexol
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 17, 2026, 10:44 AM EDT
Completed No phase listed Observational

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266
View directory record Official record
Conditions
Multiple Sclerosis, Spinal Cord Injury
Interventions
Push Notification Content
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

NCT02409459
View directory record Official record
Conditions
Iron Deficiency, Fibromyalgia
Interventions
Injectafer, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

US Phase III Study of APD421 in PONV

NCT01991860
View directory record Official record
Conditions
PONV
Interventions
APD421- Amisulpride for IV injection, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 10:44 AM EDT
Active, not recruiting Not applicable Interventional

How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

NCT07125326
View directory record Official record
Conditions
Urinary Retention, Urinary Tract Infection (Diagnosis), Postpartum Acute Urinary Retention, Postpartum Care, Voiding Dysfunction
Interventions
Intermittent catheterization, Continuous catheterization
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

NCT01899833
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
99mTc-Sestamibi
Diagnostic Test
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 17, 2026, 10:44 AM EDT
Active, not recruiting Not applicable Interventional

The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution

NCT06523985
View directory record Official record
Conditions
Carrying Naloxone/Narcan on Their Person or in Their Vehicle, Being Trained to Respond to an Opioid Overdose
Interventions
Push messages (standard), Push messages (customized)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043
View directory record Official record
Conditions
Supportive, Ill-defined Sites
Interventions
paclitaxel, docetaxel, taxane, taxane
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 10:44 AM EDT
Terminated Not applicable Interventional Results available

Neural and Behavioral Effects of Cognitive Bias Modification (CBM)

NCT04430543
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Cognitive Bias Modification, Sham Training
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 34 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 10:44 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception

NCT00349050
View directory record Official record
Conditions
Pain, Trigeminal Neuralgia, Neuropathic Pain
Interventions
laboratory pain assessment, transcranial magnetic stimulation
Device · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

NCT00039130
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
31
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization

NCT04080167
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
InCharge Health mobile application, HU Toolbox mobile application
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
15 Years to 45 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 17, 2026, 10:44 AM EDT
Terminated Phase 3 Interventional Results available

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665
View directory record Official record
Conditions
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Entospletinib, Placebo, Cytarabine, Anthracycline
Drug
Lead sponsor
Kronos Bio
Industry
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 17, 2026, 10:44 AM EDT
Not listed Phase 3 Interventional

MD.2 Medication Dispenser Medication Adherence Study

NCT00560001
View directory record Official record
Conditions
Frail Elderly, Medication Errors
Interventions
MD.2 Medication Dispenser
Behavioral
Lead sponsor
Interactive Medical Developments
Industry
Eligibility
60 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Trial of Treatments for Convergence Insufficiency

NCT00347945
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Pencil Push-ups, Office-based Vision Therapy, Placebo Office-based Vision Therapy
Procedure
Lead sponsor
Pennsylvania College of Optometry
Industry
Eligibility
9 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
7
States / cities
Fullerton, California • New York, New York • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Not applicable Interventional Results available

Mobile Health Intervention to Support Healthful Diet

NCT05236712
View directory record Official record
Conditions
Frailty
Interventions
Mobile app
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 17, 2026, 10:44 AM EDT
Completed No phase listed Observational

Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy

NCT01506518
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 13 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Motor Learning Approach for Manual Wheelchair Users

NCT03781609
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Roller system group (RG), Overground group (OG), Placebo - Wheelchair skills group (WSG)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 17, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 17, 2026, 10:44 AM EDT